Abemaciclib in combination with endocrine therapy for the treatment of HR-positive/HER2-negative locally advanced/metastatic breast cancer in the UK: an observational study
Judy King, Walid Fakhouri, Rosalind Jarvis, Waleed Badreldin, Gavin Harper, Carlo Palmieri, Mark Nathan
Springer Nature ·
2025-07-19
· DOI 10.1186/s12885-025-14526-w
The publisher did not provide an abstract — full text is available via the link below.
Judy King, Walid Fakhouri, Rosalind Jarvis, Waleed Badreldin, Gavin Harper, Carlo Palmieri et al. Abemaciclib in combination with endocrine therapy for the treatment of HR-positive/HER2-negative locally advanced/metastatic breast cancer in the UK: an observational study. // BMC Cancer. – 2025. – DOI: 10.1186/s12885-025-14526-w. – URL: https://doi.org/10.1186/s12885-025-14526-w
Judy King, Walid Fakhouri, Rosalind Jarvis, Waleed Badreldin, Gavin Harper, Carlo Palmieri, & Mark Nathan (2025). Abemaciclib in combination with endocrine therapy for the treatment of HR-positive/HER2-negative locally advanced/metastatic breast cancer in the UK: an observational study. BMC Cancer. https://doi.org/10.1186/s12885-025-14526-w
Judy King, et al. “Abemaciclib in combination with endocrine therapy for the treatment of HR-positive/HER2-negative locally advanced/metastatic breast cancer in the UK: an observational study.” BMC Cancer, 2025. doi:10.1186/s12885-025-14526-w.
@article{King2025,
title = {Abemaciclib in combination with endocrine therapy for the treatment of HR-positive/HER2-negative locally advanced/metastatic breast cancer in the UK: an observational study},
author = {King, Judy and Fakhouri, Walid and Jarvis, Rosalind and Badreldin, Waleed and Harper, Gavin and Palmieri, Carlo and Nathan, Mark},
journal = {BMC Cancer},
year = {2025},
doi = {10.1186/s12885-025-14526-w},
url = {https://doi.org/10.1186/s12885-025-14526-w}
}